EDAP TMS SA Sponsored ADR Stock

$1.67

2.62% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US2683111072

Symbol

EDAP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

EDAP TMS SA Sponsored ADR Stock price

$1.67

-0.84 33.47% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.05 2.62%

ISIN

US2683111072

Symbol

EDAP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$64.1m

Enterprise Value

$45.9m

Net debt

$-18.2m

Cash

$26.8m

Shares outstanding

37.4m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

0.87 | 0.94

EV/Sales

0.62 | 0.67

EV/FCF

negative

P/B

1.55

Financial Health

Equity Ratio

47.52%

Return on Equity

-46.50%

ROCE

-52.43%

ROIC

-90.78%

Debt/Equity

0.21

Financials (TTM | estimate)

Revenue

$73.8m | $68.6m

EBITDA

- | $-27.8m

EBIT

$-25.5m

Net Income

$-25.3m | $-28.3m

Free Cash Flow

$-23.0m

Growth (TTM | estimate)

Revenue

3.87% | -8.75%

EBITDA

- | -32.08%

EBIT

-20.14%

Net Income

-18.16% | -26.78%

Free Cash Flow

12.67%

Margin (TTM | estimate)

Gross

31.67%

EBITDA

- | -40.56%

EBIT

-34.49%

Net

-34.21% | -41.21%

Free Cash Flow

-31.10%

EPS

$-0.67

FCF per Share

$-0.61

Short interest

0.21%

Employees

310.00

Rev per Employee

$240.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

EDAP TMS SA Sponsored ADR Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a EDAP TMS SA Sponsored ADR forecast:

6x Buy

67%

3x Hold

33%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a EDAP TMS SA Sponsored ADR forecast:

Buy

67%

Hold

33%

Analyst Estimates with Stock Price Targets

Financial data from EDAP TMS SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	74 74	4% 4% 100%
- Direct Costs	43 43	3% 3% 59%
Gross Profit	23 23	20% 20% 32%
- Selling and Administrative Expenses	46 46	12% 12% 63%
- Research and Development Expense	7.07 7.07	- 10%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-25 -25	20% 20% -34%
Net Profit	-25 -25	18% 18% -34%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

EDAP TMS SA Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

about one month ago

EDAP to Present at the Jefferies Global Healthcare Conference

AUSTIN, Texas, May 27, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Global Healthcare Conference, which is being held June 3-5, 2025, in New York City. Presentation details: Date: Thursday, ...

Neutral

Seeking Alpha

●

about one month ago

EDAP TMS S.A. (EDAP) Q1 2025 Earnings Call Transcript

EDAP TMS S.A. (OTCPK:HAGHY) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants John Fraunces - IR, LifeSci Advisors Ryan Rhodes - CEO Ken Mobeck - CFO Conference Call Participants Michael Sarcone - Jefferies Sean Lee - H.C.

Neutral

GlobeNewsWire

●

about one month ago

EDAP Reports First Quarter 2025 Financial Results

Achieved a Record Number of Focal One® Robotic HIFU System Placements for a First Quarter Period Received CE Mark Designation for Focal One for the Treatment of Deep Infiltrating Endometriosis Positive Final Results of FARP Randomized Controlled Trial Presented at American Urology Association Annual Meeting (AUA 2025) Launched the New Focal One i Robotic HIFU System Performed World's First Remo...

More EDAP TMS SA Sponsored ADR News

Company Profile

EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses in the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Head office	France
CEO	Ryan Rhodes
Employees	310
Founded	1979
Website	focalone.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now